AUM Biosciences announces closing of USD $27Million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

[AUM Biosciences announces closing of USD $27Million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies] Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate. SINGAPORE, Oct. 13, 2021 /PRNewswire/ — AUM Biosciences (AUM) today announced the successful completion of USD $27 million series A funding round.

Read the source article at Intellasia East Asia News
2021-10-12 22:30:00